secondary prevention in patients with cardiovascular disease

From Aaushi
Jump to navigation Jump to search

Management

Additional terms

References

  1. Smith SC et al, AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update Circulation 2006; 113:2363 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/16702489 <Internet> http://circ.ahajournals.org/cgi/content/full/113/19/2363
  2. Smith SC et al, AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update J Am Coll Cardiol 2006; 47:2130 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16697342
  3. Prescriber's Letter 13(5): 2006 Summary of 2006 AHA/ACC secondary prevention for patients with coronary and other atherosclerotic vascular disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220707&pb=PRL (subscription needed) http://www.prescribersletter.com
  4. Prescriber's Letter 13(7): 2006 Summary of 2006 Recommendations for Primary and Secondary Prevention of Stroke Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220110&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 Gulliksson M et al. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011 Jan 24; 171:134. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21263103
  6. Smith SC et al AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update A Guideline From the American Heart Association and American College of Cardiology Foundation Circulation http://circ.ahajournals.org/content/early/2011/11/01/CIR.0b013e318235eb4d.full.pdf
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 16, 17, 19. American College of Physicians, Philadelphia 1998, 2006, 2012, 2015, 2022
  8. 8.0 8.1 Journal Watch 23(16):125, 2003 Peterson P et al Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardio 41:1445, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12742279
  9. 9.0 9.1 Wann LS et al 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Circulation Feb 15, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21321155 <Internet> http://circ.ahajournals.org/cgi/reprint/CIR.0b013e31820f14c0v1
  10. 10.0 10.1 Patel MR et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 Aug 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21830957
  11. 11.0 11.1 Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 Aug 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21870978
    Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011 Aug 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21870977
    Lopes RD et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial. Lancet 2012 Oct 2 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23036896 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60986-6/fulltext
    Vassiliou VS and Flynn PD Apixaban in atrial fibrillation: Does predicted risk matter? Lancet 2012 Oct 2 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23036897 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61673-0/fulltext
  12. 12.0 12.1 Journal Watch 24(17):133, 2004 Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo- controlled trial. Lancet. 2004 Jul 24;364(9431):331-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15276392
  13. 13.0 13.1 13.2 13.3 Armstrong MJ et al Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology May 28, 2013 vol. 80 no. 22 2065-2069 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23713086 <Internet> http://www.neurology.org/content/80/22/2065.full
  14. 14.0 14.1 Naci H and Ioannidis JPA Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24473061 <Internet> http://www.bmj.com/content/347/bmj.f5577
  15. 15.0 15.1 Paciaroni M, Bogousslavsky J. Primary and secondary prevention of ischemic stroke. Eur Neurol. 2010;63(5):267-78 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20357456
  16. 16.0 16.1 Physician's First Watch, October 29, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    cites article published in Circulation American Heart Association Secondary prevention of atherosclerotic cardiovascular disease in adults aged 65 and older. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24166575
  17. 17.0 17.1 17.2 Journal Watch. Feb 25, 2014 Massachusetts Medical Society http://www.jwatch.org
    Cote R et al. ASA failure: Does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology 2014 Feb 4; 82:382 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24384643 <Internet> http://www.neurology.org/content/82/5/382
  18. 18.0 18.1 Wang Y et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013 Jun 26 http://www.nejm.org/doi/full/10.1056/NEJMoa1215340 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23803136
  19. 19.0 19.1 19.2 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
    Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  20. Afilalo J, Duque G, Steele R et al Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008 Jan 1;51(1):37-45. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18174034 Free Article
  21. 21.0 21.1 Fleg JL, Forman DE, Berra K et al Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013 Nov 26;128(22):2422-46. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24166575 Free PMC Article
  22. 22.0 22.1 Brett AS Statins in Patients with Coronary Disease Who Are Older than 80. NEJM Journal Watch. July 28, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
    Rothschild DP, Novak E, Rich MW. Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity- Adjusted Analysis. J Am Geriatr Soc. 2016 Jul;64(7):1475-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27295083
  23. 23.0 23.1 Serban MC, Colantonio LD, Manthripragada AD Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. Journal of the American College of Cardiology Volume 69, Issue 11, March 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28302290 <Internet> http://www.onlinejacc.org/content/69/11/1386
    Nissen SE Statin Intolerance. An Elusive But Morbid Disorder. Journal of the American College of Cardiology Volume 69, Issue 11, March 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28302291 <Internet> http://www.onlinejacc.org/content/69/11/1396
  24. 24.0 24.1 Li L, Geraghty OC, Mehta Z et al Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. Jun 13, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26227434 Free full text <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30770-5/fulltext
    Diener HC Preventing major gastrointestinal bleeding in elderly patients. Lancet. Jun 13, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28622952 Free Article <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31507-6/fulltext
  25. 25.0 25.1 25.2 Lloyd-Jones DM, Morris PB, Ballantyne CM et al 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol Sept 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28886926 <Internet> http://www.onlinejacc.org/content/early/2017/08/30/j.jacc.2017.07.745
    Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM et al 2016 ACC Expert Consensus Decision Pathway on the Role of Non- Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27046161 Free Article
  26. 26.0 26.1 Levine GN, Lange RA, Bairey-Merz CN et al Meditation and Cardiovascular Risk Reduction A Scientific Statement From the American Heart Association. J Am Heart Assoc. Sept 28, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28963100 Free full text <Internet> http://jaha.ahajournals.org/content/6/10/e002218
  27. 27.0 27.1 Bach RG, Cannon CP, Giugliano RP et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: A secondary analysis of a randomized clinical trial. JAMA Cardiol 2019 Jul 17; PMID: https://www.ncbi.nlm.nih.gov/pubmed/31314050 https://jamanetwork.com/journals/jamacardiology/fullarticle/2738104
    Grotto AM Jr. Intensive lipid lowering in elderly patients. JAMA Cardiol 2019 Jul 17 Not indexed in PubMed https://jamanetwork.com/journals/jamacardiology/fullarticle/2738100
  28. 28.0 28.1 Chiarito M et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis. Lancet 2020 May 9; 395:1487. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32386592 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30315-9.pdf
  29. 29.0 29.1 Mohan D, Mente A, Dehghan M et al. Associations of fish consumption with risk of cardiovascular disease and mortality among individuals with or without vascular disease from 58 countries. JAMA Intern Med 2021 Mar 8; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/33683310 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2777338
  30. 30.0 30.1 Gragnano F et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol 2023 Jul 11; 82:89 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37407118 https://www.sciencedirect.com/science/article/abs/pii/S0735109723055936
  31. 31.0 31.1 31.2 Aguilar-Salinas CA, Gomez-Diaz RA, Corral P. New therapies for primary hyperlipidemia. J Clin Endocrinol Metab. 2022;107:1216-1224. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34888679
  32. 32.0 32.1 Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023 Nov 11; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37952131 https://www.nejm.org/doi/10.1056/NEJMoa2307563
  33. 33.0 33.1 Hansen MK et al Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction. J Am Coll Cardiol. 2024 Mar, 83 (9) 956-958 PMID: https://www.ncbi.nlm.nih.gov/pubmed/384180 https://www.jacc.org/doi/10.1016/j.jacc.2023.12.029